

**NEW YORK STATE MEDICAID  
PREFERRED DRUG PROGRAM  
2014 THERAPEUTIC CLASS REVIEW**

The New York Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2014 as they pertain to the Preferred Drug Program (PDP) (see table below). For these therapeutic classes new relevant clinical and/or financial information, since the previous review of the class, is known to exist. DUR Board meeting agendas for 2014 are under development and will be posted on the Department of Health (DoH) web-site thirty (30) days prior to the meeting date.

<b>Therapeutic Category</b>	<b>Therapeutic Class</b>	<b>Previous Review Date</b>
Analgesics	Non Steroidal Anti-inflammatory Drugs	April 19, 2012
	Opioids – long acting	June 27, 2013
Anti-Infectives	Hepatitis C – Direct Acting Antivirals	June 27, 2013
Central Nervous System	Anticonvulsants – second generation	June 27, 2013
	Antipsychotics – second generation	April 19, 2012
	Carbamazepine Derivatives	June 27, 2013
	Central Nervous System Stimulants	April 19, 2012
	Multiple Sclerosis Agents	June 27, 2013
	Selective Serotonin Reuptake Inhibitors	June 27, 2013
	Serotonin-Norepinephrine Reuptake Inhibitors	April 19, 2012
Dermatological	Anti-Fungals	June 16, 2011
	Anti-Infectives	June 27, 2013
Endocrine/Metabolic	Growth Hormones	June 27, 2013
	Thiazolidinediones (TZDs)	June 16, 2011
Gastrointestinal	Sulfasalazine Derivatives	June 15, 2012
Hematologicals	Platelet Inhibitors	June 27, 2013
Immunologics	Immunomodulators - systemic	June 27, 2013

Ophthalmics	Alpha-2 Adrenergic Agonists (for glaucoma)	June 11, 2010
	Prostaglandin Agonists	June 15, 2012
Renal/Genitourinary	Phosphate Binders/Regulators	June 15, 2012
Respiratory	Anticholinergics/COPD Agents	June 27, 2013
	Antihistamines - second generation	June 27, 2013
	Corticosteroids - inhaled	June 27, 2013
	Corticosteroid/Long Acting Beta Agonist Combinations	April 19, 2012
	Corticosteroids - intranasal	June 27, 2013

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at [https://newyork.fhsc.com/downloads/providers/NYRx\\_PDP\\_PDL.pdf](https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf)

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the DoH proposes no changes to the established Commissioner's final determinations. If interested parties have new relevant clinical information, please submit to the Medicaid Pharmacy Department ([dur@health.state.ny.us](mailto:dur@health.state.ny.us)) in a timely manner. The DoH will consider any new relevant clinical information provided when developing future DUR Board meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on previous meeting agendas which may be viewed at [http://www.health.ny.gov/health\\_care/medicaid/program](http://www.health.ny.gov/health_care/medicaid/program)

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged.

- Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to [dur@health.state.ny.us](mailto:dur@health.state.ny.us) (please reference DUR Board re-review).
- Clinical information submitted in reference to a DUR Board meeting agenda must be received by the DoH no later than two (2) weeks prior to the meeting date or the DUR Board may not have ample time to review the information.

Please continue to monitor the DoH web-site for DUR Board meeting schedules and agendas. ([http://www.health.ny.gov/health\\_care/medicaid/program/pharmacy.htm](http://www.health.ny.gov/health_care/medicaid/program/pharmacy.htm))

Posted: 3/24/2014